Endovascular aortic aneurysm repair (EVAR) has become an acceptable alternative to open surgery for abdominal aortic aneurysms (AAA). Many will attest that EVAR has become the standard of care in patients who meet anatomic criteria. Current data suggests that EVAR is associated with a lower 30-day morbidity and mortality, improved quality of life, reduced blood loss, and shorter recovery period compared to open repair. However, it must be recognized that EVAR is not risk-free and associated with an adverse event rate of 11–30% and may require secondary interventions in 19–24% of cases. Adverse events are subtly different from open repair and can be systemic, device-related, or access site-related. Physicians performing EVAR must remain attentive to potential adverse events and be well-versed in the treatment options. Lifelong post-procedure imaging surveillance is recommended in all patients following EVAR to assess long-term endograft performance.